Neuregulin based methods and compositions for treating cardiovascular diseases
AssigneeZensun (Shanghai) Science & Technology, Co., Ltd.
InventorMingdong Zhou
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin.
Claims26
A combination, which combination comprises an effective amount of a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin, and an effective amount of a prophylactic or therapeutic agent for viral myocarditis or dilated (congestive) cardiomyopathy (DCM).
2-5. (canceled)
7-10. (canceled)
12-16. (canceled)
19-46. (canceled)
A pharmaceutical composition for preventing, treating or delaying viral myocarditis or dilated (congestive) cardiomyopathy (DCM) in a mammal, which pharmaceutical composition comprises an effective amount of a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a NRG protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin.
48-51. (canceled)
55-82. (canceled)
A combination, which combination comprises an effective amount of a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin, and an effective amount of a prophylactic or therapeutic agent for myocardial infarction.
84-87. (canceled)
96-124. (canceled)
Dependencies are inferred from the claim text.